Guest Post | Advt. | Query: info@techrecur.com

PAREXEL Navigates China’s Complex Drug Development and Market Landscape for Global Biopharmaceutical Companies with New China Advisory Service


BOSTON, October 31, 2018 – PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, today announced that the Company has launched a new China Advisory Service to help global biopharmaceutical companies participate in the growing, yet complex market opportunity within China. The offering leverages PAREXEL’s deep experience with and knowledge of the Chinese biopharmaceutical landscape to help companies navigate all aspects of the country’s drug development process. This includes overall strategy, agency engagement and agreements, early development, clinical operations, and regulatory, market access, and commercial strategies.
China’s regulator, the National Medicinal Products Administration (NMPA, formerly CFDA), has undergone significant reform in recent years, including the introduction of expedited approval pathways, acceptance of data from Multiregional Clinical Trials (MCRTs) to support marketing applications, first-in-human studies and Clinical Trial Approvals (CTAs) in 60 days. While these reforms have made the regulatory environment in China more accessible to global pharmaceutical companies, significant barriers to entry remain. These barriers include government-mandated price controls in public medical insurance programs, complex price negotiation processes at national and province levels, complex distribution channels, infrequently updated formularies, and an absence of GMP-compliant manufacturing testing sites and GCP-compliant clinical sites.

“The Chinese government is committed to becoming a major player in the global pharmaceutical industry and in recent years significant changes have been made with the goal of assessing novel therapies for its population and bringing China to the forefront of drug development,” said Chang Lee, M.D., MSHA, DrPH, Vice President of Consulting for PAREXEL in China. “These changes have come very quickly and have resulted in an extremely dynamic landscape for companies looking to enter the market. The ability to quickly understand and adapt to these changes is critical to succeeding in this rapidly-changing environment.”

The China Advisory Service aims to guide global biopharmaceutical companies as they evaluate the market opportunity in China, become a Marketing Authorization Holder (MAH), ensure compliance with NMPA, attain favorable formulary status and pricing, and commercialize safe and compliant drugs in the market. Leveraging PAREXEL’s operational experience in conducting phase I-IV clinical research in China, the Company’s dedicated team based in China includes several ex-NMPA personnel and global regulatory leaders, as well as dedicated regulatory consultants and market access experts. PAREXEL teams have also been part of the process to shape local policies, including working with the NMPA to support guideline development and Center for Drug Evaluation (CDE) education programs, and participating in new policy discussions, research project and CDE meetings.

“In just a short time, China has grown from being an emerging market for companies looking to develop drugs to the second largest biopharmaceutical market in the world. While many are aware of the opportunity that exists in the market, the challenges and hurdles to entry are generally not well understood,” said Paul Bridges, Corporate Vice President and Worldwide Head of Consulting, PAREXEL. “PAREXEL has significant first-hand experience working in China and with local regulators, and with this offering we aim to partner with our clients as they consider and navigate this exciting yet complex market opportunity.”

PAREXEL has been operating in China for more than 19 years and currently employs more than 1,400 employees in seven offices across the country. For more information about PAREXEL’s China Advisory Services visit the website or read more from PAREXEL’s experts here: https://regulatory.parexel.com/china-advisory-services.

About PAREXEL International
PAREXEL International Corporation is a leading innovator of global biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation. All other trademarks are the property of their respective owners.

# # #

PAREXEL Contacts:
Media:
Wendy Ryan
Tel.: +1 781-434-5104
Email: Wendy.Ryan@PAREXEL.com

Kathryn McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300
Email: PAREXEL@pancomm.com

Have any Question or Comment?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

::::::::::::::::::::::::::::::::::3451:::::::::::::::::::::::::::::::::;;

::::::::::::::::::::::::::::::::::6733:::::::::::::::::::::::::::::::::;;

:::::::::::::::::::::::::::::925:::::::::::::::::::::::::::::::

TRIO STEEL IS ONE OF THE MOST TRUSTED BRAND AND LEADING EXPORTER AND SUPPLIER OF CARBON STEEL, ALLOY STEEL & STAINLESS STEEL PIPES & PIPE FITTINGS MATERIAL. Triosteel is one of the leading Suppliers and Exporters of API 5L Pipe in Singapore. Triosteel also Exports to many countries like Indonesia, Iran, Saudi Arabia & many more. An API 5L pipe is manufactured by adhering to the specifications laid down by the International Organization for Standardization (ISO) 3183.

::::::::::::::3453:::::::::::::

2780

buy! buy! CHEAP! Telefonie VoIP CHEAP! buy! buy! CHEAP!

2781

buy! buy! CHEAP! Telefonie VoIP CHEAP! buy! buy! CHEAP!

——————————————–

For the 2012 MLB period, we found an totals forecast Joao’s Renowned Over/Under João Zorro Gonçalves, Zcode Totals Pro, System of the time with progressions that have been successful over 98 98% ... We eventually perfected our over/under program ( Zcodesystemexclusive ), although it h-AS has brought years of investigation. Five Steps to Making a Winning MLB Method: 1. Execute appropriate cash management tools. 2. MLB rules that are comprehend. 3.Extensive testing back to make sure successful longterm results ...

——————————————–

There is always a challenge when you're dealing with the Foreign Exchange Market. That's just the nature of the beast. The best thing you can do is to learn about how the market operates as a whole so that you will be ready to meet these challenges. iq option penipu Never be misled by any profit gains in binary options. This is the number-one way traders end up losing their money and ultimately failing. Remember that the same things that make you laugh can make you cry in this market, and you can lose that $700.

——————————————–

Learning Polish has never been this fun and easy as with our podcasts Learn Polish with Polishpod101 Start today and become conversational in Polish in no time

——————————————–

The Best Website Agen Poker Resmi www.sakupoker.com Terpercaya come join

——————————————–

Do you need edmonton phone systems service ? Call complete communications today!

——————————————–

High-tech solutions for easy start-up of your IPTV/OTT-business

——————————————–

——————————————–

If you want to purchase not only one item, you have a chance to enjoy privileges. There is a sale’ tab on the site which offers a fantastic range of reduced counterfeit watches and accessories, such as sunglasses, cufflinks, watch straps and pens. Luxury Jewelry Replica At MCA.MN On Sale You get a 5% discount if you buy two pieces, this discount increases to 10% if you buy 4 pieces or more. There is free international shipping on all orders on this site. We also offer customers a free return anytime with a 100% money back guarantee.

——————————————–

:::::::::::::::::3452:::::::::::::::::::